0001193125-22-289487.txt : 20221121 0001193125-22-289487.hdr.sgml : 20221121 20221121070055 ACCESSION NUMBER: 0001193125-22-289487 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20221118 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221121 DATE AS OF CHANGE: 20221121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000818686 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16174 FILM NUMBER: 221403462 BUSINESS ADDRESS: STREET 1: 5 BAZEL ST STREET 2: P O B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 BUSINESS PHONE: 9729267267 MAIL ADDRESS: STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED STREET 2: 5 BAZEL ST PO B 3190 CITY: PETACH TIKVA STATE: L3 ZIP: 49131 8-K 1 d284218d8k.htm 8-K 8-K
TEVA PHARMACEUTICAL INDUSTRIES LTD 00-0000000 false 0000818686 0000818686 2022-11-18 2022-11-18

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 18, 2022

 

 

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(Exact name of registrant as specified in its charter)

 

 

 

Israel   001-16174   Not Applicable

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

 

124 Dvora Hanevi’a Street
Tel Aviv 6944020, Israel
(Address of Principal Executive Offices, including Zip Code)

+972-3-914-8213

(Registrant’s Telephone Number, including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Copies of communications to:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

American Depositary Shares, each representing one Ordinary Share   TEVA   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

ITEM 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On November 21, 2022, Teva Pharmaceutical Industries Ltd. (the “Company”) announced that its Board of Directors had appointed Richard Francis to become the Company’s President and Chief Executive Officer, effective January 1, 2023. In order to facilitate an orderly transition, Kåre Schultz and the Company’s Board of Directors have mutually agreed that Mr. Schultz will retire from his current positions as President and Chief Executive Officer, and a member of the Board of Directors, effective December 31, 2022.

Mr. Francis, age 54, is a seasoned pharmaceutical executive bringing over two decades of experience to the Company, including five years as Chief Executive Officer of Sandoz and a member of the Novartis Executive Team from 2014 to 2019. Prior to his role at Sandoz, Mr. Francis was a senior executive at Biogen for 13 years where he held a number of senior roles, including leading the U.S. business. He also oversaw the successful launch of Tecfidera® in 2013. Mr. Francis has served as the CEO of Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, since 2021, and as CEO of Forcefield Therapeutics, a pioneer of best-in-class therapeutics to protect heart function, since 2021. He has also served as an operating partner for Syncona Investment Management Limited since 2021. Mr. Francis also serves as a member of the board of directors of Mettler-Toledo International Inc.

Mr. Francis and the Company have entered into an employment agreement (the “Employment Agreement”), which provides for an initial employment term of three years, subject to automatic renewal for successive one-year periods unless either party gives at least six months advance notice of non-renewal or termination. Under the Employment Agreement, Mr. Francis will receive an annual base salary of USD $1.6 million, a target annual bonus opportunity equal to 150% of his annual base salary (and a maximum opportunity of 200% of his annual base salary), annual equity incentives with a total target grant date fair value of USD $9 million, 70% of which will be in the form of performance stock units (“PSUs”) and 30% in the form of restricted stock units (“RSUs”), and the same employee benefits as are provided to similarly situated senior executives of the Company. Upon commencing employment, in light of forfeited compensation opportunities at his prior employer and to incentivize him to join the Company, Mr. Francis will also receive (a) the following sign-on equity awards: (i) an RSU award with a grant date fair value of USD $5 million, which will vest in equal installments on the first, second and third anniversaries of the grant date, subject to his continued employment through the applicable vesting dates; and (ii) a PSU award with a target grant date fair value of USD $5 million, which will be earned based on the achievement of stretch performance goals to be established by the Human Resources & Compensation Committee of the Board prior to the 2023 annual meeting of shareholders, and (b) a sign-on cash award of USD $5 million, which will vest and be paid in three installments, with the first installment, equal to $1,500,000, to be paid on the first business day following the date that Mr. Francis commences employment with the Company (the “Effective Date”), the second installment, equal to $1,500,000, to be paid on the first business day following the first anniversary of the Effective Date, and the third installment, equal to $2,000,000, to be paid on the first business day following the third anniversary of the Effective Date, in each case subject to his continued employment through the applicable vesting date. In connection with rendering services from the Company’s principal offices in Israel, Mr. Francis will also receive certain housing and travel reimbursements, annual allowance for financial and tax advisory fees, and certain other relocation benefits in accordance with the Company’s policies. The Employment Agreement also provides for a one-time legal fee reimbursement.

If Mr. Francis’s employment were terminated by the Company without “cause” or by him for “good reason” (each term as defined in the Employment Agreement), he would be entitled to, as of the date of termination: (a) cash severance equal to two times his annual base salary; (b) vesting (on the later of the date of termination and the first anniversary of the grant date) of any portion of the sign-on RSU award that is unvested; (c) vesting of the portion of the sign-on PSU award that is earned based on actual performance at the end of the applicable performance period; (d) vesting of any portion of the sign-on cash award that is unvested; (e) if Mr. Francis has been employed by the Company for at least 12 months, a prorated annual bonus for the year of termination, determined based on actual performance; and (f) if the date of termination occurs within the first year following a change in control of the Company, an additional cash severance payment equal to his annual base salary. In addition, in consideration for Mr. Francis’s compliance with certain restrictive covenants including noncompetition covenants, Mr. Francis shall be entitled to payment of 12 months of his base salary, payable in 12 equal monthly installments following the date of termination for any reason other than due to his death or termination for cause by the Company. All severance benefits (other than any portion required under applicable law) and the noncompete payment are subject to

 

2

Mr. Francis’s execution of a release of claims in favor of the Company and compliance with the restrictive covenants included in the Employment Agreement, which consist of a 12-month post-termination noncompetition covenant, a 24-month post-termination nonsolicitation covenant, a perpetual confidentiality covenant and a 10-year post-termination nondisparagement covenant.

There are no arrangements or understandings between Mr. Francis and any other person pursuant to which Mr. Francis was appointed to serve as President and Chief Executive Officer of the Company. There are no family relationships between Mr. Francis and any director or executive officer of the Company, and Mr. Francis has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

In connection with the leadership transition, Mr. Schultz and the Company entered into a letter agreement summarizing the terms of his departure, including that he will continue to serve as President and Chief Executive Officer and a member of the Board of Directors through December 31, 2022 and will thereafter be placed on garden leave until the expiration of his contractual notice period on February 19, 2023. During the garden leave period, Mr. Schultz has agreed to be available to assist with the transition. Mr. Schultz’s termination of employment will be treated as a termination without cause under his employment agreement with the Company, which will entitle him to the applicable payments and benefits specified in his employment agreement during his notice period and upon termination of employment, subject, to the extent applicable, to his execution and non-revocation of a release of claims in favor of the Company and compliance with the restrictive covenants set forth in his employment agreement.

A copy of the Company’s press release relating to the leadership transition is attached to this Current Report on Form 8-K as Exhibit 99.1.

 

ITEM 9.01

Financial Statements and Exhibits

(d) Exhibits.

 

Exhibit No.   

Description

99.1    Press Release, dated November 21, 2022

 

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Date: November 21, 2022     By:  

/s/ Eli Kalif

    Name:   Eli Kalif
    Title:   Executive Vice President, Chief Financial Officer

 

4

EX-99.1 2 d284218dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO    LOGO

Teva Announces Appointment of Richard Francis as President and CEO

Kåre Schultz to Retire After a Transformative Five-Year Tenure Setting the Stage for an Exciting Future

TEL AVIV, Israel – November 21, 2022 – Teva Pharmaceutical Industries Ltd. (“Teva” or the “Company”) (NYSE and TASE: TEVA), today announced that the Company’s Board of Directors has appointed Richard Francis as President and Chief Executive Officer, effective January 1, 2023. In order to facilitate an orderly transition, Kåre Schultz and the Teva Board of Directors have mutually agreed that Mr. Schultz will retire from his current position as Chief Executive Officer, effective December 31, 2022.

Mr. Francis is a seasoned pharmaceutical executive bringing more than two and a half decades of experience to Teva, including five years as Chief Executive Officer of Sandoz and a member of the Novartis Executive Team. Prior to his role at Sandoz, Mr. Francis was a senior executive at Biogen for 13 years where he held a number of senior roles, including leading the U.S. business. He also oversaw the successful launch of Tecfidera® in 2013. Mr. Francis is currently the CEO of Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, and CEO of Forcefield Therapeutics, a pioneer of best-in-class therapeutics to protect heart function. He is also an operating partner for Syncona Investment Management Limited.

“It has been a great privilege to serve Teva as its CEO since 2017, and to work with our dedicated and talented team to improve the lives of patients,” said Mr. Schultz. “We have positioned Teva as a leader in both our specialty and generics businesses, built a strong financial and operational foundation and enhanced our portfolio and pipeline. This is the right time for a transition, and Richard’s proven track record in the industry makes him the right person to serve as Teva’s next CEO.”

“On behalf of the entire Board, I would like to thank Kåre for his dedication and contributions to Teva over the last five years,” said Dr. Sol J. Barer, Chairman of Teva’s Board of Directors. “Under Kåre’s leadership, we have stabilized the business and undergone a significant operational transformation across our international footprint. The Company is now well positioned for an exciting future and, by leveraging Richard’s compelling track record of growing businesses in the life sciences, biologics and generic drug sectors, his entrepreneurial and pragmatic leadership style and emphasis on a collaborative and innovative culture, the Board and I are confident that Teva will build on this solid foundation. As a global enterprise, we look forward to furthering our mission to provide much needed medicines to even more patients around the world under Richard’s leadership. The Board is delighted to have found the ideal leader for the next phase in Teva’s exciting journey to return to growth and leadership.”

 

    

 

IR Contacts   

Ran Meir

 

Yael Ashman

   

(267) 468-4072

 

972 (3) 914-8262

   

LOGO

PR Contacts   

Kelley Dougherty

 

Eden Klein

   

(973)-832-2810

 

972 (3) 906 2645

   

LOGO    LOGO

 

“I have long been impressed with the value Teva provides to patients globally and I am honored to take on the role of leading this extraordinary company into the future,” said Mr. Francis. “I look forward to leveraging my background and years of pharmaceutical experience to build on Teva’s strong fundamentals and to write the next exciting chapter for Teva, focusing on building a solid pathway to deliver long-term growth. I continue to see a bright future ahead for the Company and look forward to working closely with the Board, management team and talented employees to continue driving value creation for patients, employees, shareholders and other stakeholders.”

About Richard Francis

Richard Francis is an operating Partner at Syncona, which focuses on founding, building and funding healthcare companies. Mr. Francis is the Chief Executive Officer of Syncona’s portfolio companies, Purespring Therapeutics, one of the first AAV gene therapy companies focused on the kidney globally, and Forcefield Therapeutics, a pioneer of best-in-class therapeutics to retain heart function via protection of cardiomyocytes.

Prior to his current roles, Mr. Francis spent five years as the Chief Executive Officer of Sandoz and a member of the Novartis Executive Team. During Mr. Francis’ time at Sandoz, he developed a transformative strategy to reshape the business by focusing the organization on key geographies, reshaping the portfolio and targeting efficiencies to drive growth and margin improvement. Mr. Francis held various leadership roles over a 13-year tenure at Biogen, including Senior Vice President of U.S. Commercial, Vice President / Senior Vice President of Global Commercial Strategy, Managing Director of Canada and Managing Director of the UK and Ireland. During his time at Biogen, Mr. Francis oversaw the growth of the U.S. Commercial business, driven by a strategic focus on commercial excellence. To that end, at Biogen, Mr. Francis led the successful launch of Tecfidera® in 2013. Earlier in his career, Mr. Francis worked at Sanofi and Wyeth.

Mr. Francis holds a Bachelor of Arts in Economics from The Manchester Metropolitan University.

 

    

 

IR Contacts   

Ran Meir

 

Yael Ashman

   

(267) 468-4072

 

972 (3) 914-8262

   

LOGO

PR Contacts   

Kelley Dougherty

 

Eden Klein

   

(973)-832-2810

 

972 (3) 906 2645

   

LOGO    LOGO

 

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic, biosimilar and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to our ability to attract, hire and retain highly skilled personnel; our ability to successfully compete in the marketplace, including our ability to develop and commercialize biopharmaceutical products, competition for our specialty products, including AUSTEDO®, AJOVY® and COPAXONE®; our ability to achieve expected results from investments in our product pipeline, our ability to develop and commercialize additional pharmaceutical products, and the effectiveness of our patents and other measures to protect our intellectual property rights; our substantial indebtedness; our business and operations in general; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to the COVID-19 pandemic; compliance, regulatory and litigation matters, including failure to comply with complex legal and regulatory environments; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the third quarter of 2022 and in our Annual Report on Form 10-K for the year ended December 31, 2021, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

# # #

 

    

 

IR Contacts   

Ran Meir

 

Yael Ashman

   

(267) 468-4072

 

972 (3) 914-8262

   

LOGO

PR Contacts   

Kelley Dougherty

 

Eden Klein

   

(973)-832-2810

 

972 (3) 906 2645

   
EX-101.SCH 3 teva-20221118.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 teva-20221118_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Entity Tax Identification Number Entity Tax Identification Number Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, Country Entity Address, Country City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 teva-20221118_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g284218g01a02.jpg GRAPHIC begin 644 g284218g01a02.jpg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end GRAPHIC 7 g284218g63n72.jpg GRAPHIC begin 644 g284218g63n72.jpg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end GRAPHIC 8 g284218g80o96.jpg GRAPHIC begin 644 g284218g80o96.jpg M_]C_X 02D9)1@ ! $ 8 !@ #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC M+B!6,2XP,0#_VP"$ @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\< M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3H.$A8:' MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7 MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1 (! @0$ P0'!00$ $"=P ! @,1 M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6& MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76 MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_ !$( -@ U@,!$0 "$0$#$0'_V@ , M P$ A$#$0 _ /?R<#- &/>^)]*TYL7DTT'N]K*!^>W%0YQ6YR5,;1I?&VOD M_P#(I_\ ">^&?^@E_P"0)/\ XFE[6'&STU+_R#)_\ $TO:P74I9GA7M/\ !_Y#AXW\ M.GIJ/_D&3_XFE[:GW*_M##?S?@_\A1XU\/'IJ'_D%_\ XFCV]/N5]>P_\WX/ M_(7_ (3/0/\ G_\ _(+_ /Q-'MZ?UAW%_M_3/\ GY_\<;_"CZU2[_F'M(]Q?[>T MW_GY_P#'&_PI?6J7?\Q^TCW+%K?VU[O^SR;]F,_*1C/U^E:TZL*GPL:DI;%F MM"@H * $9592K $'J#0#5S"U#P=H6I9,M@DMAOXD2M'(IZ&LFF$)Q9.M0=*)5I&B'K2-$2"I+1(M( MM#QUH*0\4%(>*10\=*1:'B@8X4BAXH&/%(I#Q04/% QXH*'K2&/% SI/"W_+ MW_P#^M>C@?M?+]3HI=3HJ]$V"@ H * "@ H 1D5U*NH93P01D&@32:LSE]6\ M!:-J.Z2&,V?F%<]C",^Y.C ]#4LWBTR45) MHB1:1:'CK04AXH*0\4BAXZ4BT/% QPI%#Q0,>*12'B@H>*!CQ04/6D,>*!G2 M>%O^7O\ X!_6O1P/VOE^IT4NIT5>B;!0 4 % !0 4 % !0 4 8.L>$M+U<,[ M1>1<'_EK$,'\1T-93I1F<=?!4JVK5GW//M8\)ZEHI,C)Y]L/^6L8Z?4=JX:E M&4/0\6M@ZE'7==S(20CKR*PL8QDT6$8,.*FUC:+3)1UI&B'B@I#Q2*'CI2+0 M\4#'"D4/% QXI%(>*"AXH&/%!0]:0QXH&=)X6_Y>_P#@']:]' _:^7ZG12ZG M15Z)L% !0 4 % !0 4 % !0 4 ! (P>E '*ZYX)L]0W3V6VUN>N /D;ZCM^% M?7P,*FL-&>?W^FW>EW!@NX6B<=#V;W![UP2C*#LSR)TITG:2(D MD(Z\UG8<96W+"D$<&D;)W)!2*'CI2+0\4#'"D4/% QXI%(>*"AXH&/%!0]:0 MQXH&=)X6_P"7O_@']:]' _:^7ZG12ZG15Z)L% !0 4 % !0 4 % !0 4 % ! M0!6OM/M=1MFM[J%9(SV/4>X/:IE%25F1.G&HN62/.]=\(W.E;KBUW7%IU/'S M)]?4>]>=5H.&JV/'KX25/6.J.=7(.0:YCD6FQ8CDSPW!J;&T9=R<4C5#Q0,< M*10\4#'BD4AXH*'B@8\4%#UI#'B@9TGA;_E[_P" ?UKT<#]KY?J=%+J=%7HF MP4 % !0 4 % !0 4 % !0 4 % !0 8XQ0!R'B#P]#.HJ;%QE8LJ0 M1D4C9.X\4BAXH&/%(I#Q04/% QXH*'K2&/% SI/"W_+W_P _K7HX'[7R_4Z M*74Z*O1-@H * "@ H * "@ H * "@ H * "@ H * ,/7_#D&L1F5,17:CY7[ M-[&N>M05176YS5\/&KJMSSFYM)[*Y>WN(S'*AY!KRY1<79GDR@X.TABDJ*"AZTACQ0,Z3PM_R]_\ /ZUZ.!^ MU\OU.BEU.BKT38* "@ H * "@ H * "@ H * "@ H * "@ H R]:T2WUBVVO M\DRC]W(!R/\ ZU8U:2J+4QJT8U59[GFUY8SZ?=/;W*;9%_(CU'M7DSBX.S/) ME!P=F0C(.14"6A9C?=P>#2-8NY**1:'B@H>*!CQ04/6D,>*!G2>%O^7O_@'] M:]' _:^7ZG12ZG15Z)L% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &;K. MC0:O:^6X"RK_ *N3NI_PK&K2516,JM)5%9GFUU9S6-T]O<)MD0_G[CVKR91< M'9GDR@X.S(NG2H L1ONX/6D:1=R84C0>*!CQ04/6D,>*!G2>%O\ E[_X!_6O M1P/VOE^IT4NIT5>B;!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 9.N MZ)'J]KQA+E!^[?\ H?:L*U%5%YF-:DJB\SSF6&2WF>*5"DB'#*>QKR&G%V9Y M;33LQ!Q2 L1ON&#UJ36+N3"@L>*"AZTACQ0,Z3PM_P O?_ /ZUZ.!^U\OU.B MEU.BKT38* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H Y[Q-H?V^'[ M5;K_ *3&.0/XQZ?6N3$T>=4>>.7@YH&BRC;A[TC5.Y** M"QZTACQ0,Z3PM_R]_P# /ZUZ.!^U\OU.BEU.BKT38* "@ H * "@ H * "@ MH * "@ H * "@ H * "@ H * .+\4Z+]GD-_;IB)S^\4?PGU_&O-Q5'E?/$X M:]*SYD*!G2>%O\ E[_X!_6O1P/VOE^I MT4NIT5>B;!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 R6))HF MBD4,C#!![BDTFK,32:LSSK5M,?2[YH3DQGF-O45XM:FZ4K'FU(_^ ?UKT<#]KY?J=%+J=%7HFP4 % !0 4 % !0 4 % !0 M4 % !0 4 % !0 4 % !0 4 % !0!!>6L=Y:26\@^5QCZ'UJ)P4XN+)E%25F> M=SP/;3R0R##H<&O#E%Q=F<#5G88!4@21G!Q2&CJ/"O\ R]_\ _K7HX'[7R_4 MZJ74Z*O1-@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H M Y;Q5889+Y!U^1_Z&O.QE/::.:M'[1S@%>>5C*?+/F74YJL M;.YB@8KB,CI/"O'VO_@']:]' _:^7ZF]'J='7HFX4 % !0 4 % !0 4 % !0 M 4 % !0 4 % !0 4 % !0 4 % !0 4 % &?K5K]JTR50,NGSK]17/B(<]-HB M:O$XD5XIR'1^%?\ E[_X!_6O1P/VOE^IO2ZG1UZ)N% !0 4 % !0 4 % !0 M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 $<8H X/4+;[+J$T.,!6ROT/2O M!JPY)N)R25G8VO"W'VO_ (!_6NW _:^7ZFM+J=%7HFP4 % !0 4 % !0 4 % M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!S/B:WVSPW '##:?J.E>9C M86:D855K=I4A YC(:F M_(BHKQ,_PM_R]_\ /ZUSX'[7R_4BEU.BKT38* "@ H * "@ H * "@ H * M"@ H * "@ H * "@ H * "@ H * "@ H 9+&)87C/1E(I25TT)ZF%X94H]XA MZJ5!_P#'JX,$K.2_KJ94M+G05Z!L% !0 4 % !0 4 % !0 4 % !0 4 % !0 M 4 % !0 4 % !0 4 % !0 4 % &5ID7DZIJ2XP"R,/QR:Y:,>6I->AG%6DS5 MKJ- H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ >H B2!$N))AG=( #Z<9_QJ5%*3EW%:SN2U0PH __9 end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Document and Entity Information
Nov. 18, 2022
Cover [Abstract]  
Entity Registrant Name TEVA PHARMACEUTICAL INDUSTRIES LTD
Entity Tax Identification Number 00-0000000
Amendment Flag false
Entity Central Index Key 0000818686
Document Type 8-K
Document Period End Date Nov. 18, 2022
Entity Incorporation State Country Code L3
Entity File Number 001-16174
Entity Address, Address Line One 124 Dvora Hanevi’a Street
Entity Address, City or Town Tel Aviv
Entity Address, Postal Zip Code 6944020
Entity Address, Country IL
City Area Code 972
Local Phone Number 3-914-8213
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title American Depositary Shares, each representing one Ordinary Share
Trading Symbol TEVA
Security Exchange Name NYSE
Entity Emerging Growth Company false
XML 10 d284218d8k_htm.xml IDEA: XBRL DOCUMENT 0000818686 2022-11-18 2022-11-18 TEVA PHARMACEUTICAL INDUSTRIES LTD 00-0000000 false 0000818686 8-K 2022-11-18 L3 001-16174 124 Dvora Hanevi’a Street Tel Aviv 6944020 IL 972 3-914-8213 false false false false American Depositary Shares, each representing one Ordinary Share TEVA NYSE false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - d284218d8k.htm 7 d284218d8k.htm d284218dex991.htm teva-20221118.xsd teva-20221118_lab.xml teva-20221118_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d284218d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d284218d8k.htm" ] }, "labelLink": { "local": [ "teva-20221118_lab.xml" ] }, "presentationLink": { "local": [ "teva-20221118_pre.xml" ] }, "schema": { "local": [ "teva-20221118.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "teva", "nsuri": "http://www.tevapharm.com/20221118", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d284218d8k.htm", "contextRef": "duration_2022-11-18_to_2022-11-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d284218d8k.htm", "contextRef": "duration_2022-11-18_to_2022-11-18", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.tevapharm.com//20221118/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 18 0001193125-22-289487-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-289487-xbrl.zip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end